Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Honghao Yang, Clara Kim(United States Food and Drug Administration), Bernard Regidor, Shahrooz Eshaghian(Cedars-Sinai Medical Center), Benjamin Eades(James Madison University), Tahmineh Safaie(Oncotherapeutics (United States)), Susanna Kim(Oncotherapeutics (United States)), Sean Bujarski, Gary E. Schwartz, Mehdi M. Moezi, Stephen Lim(Cedars-Sinai Medical Center), Daisy Martinez(Oncotherapeutics (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Regina A. Swift(Institute for Myeloma & Bone Cancer Research)
Cited by 2
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425